Inv(3) Acute Myeloid Leukemia in a Young Adult and Review of the Literature

Carlee Blakemore; Sudarshawn Damodharan; Diane Puccetti

doi:10.1155/2023/6628492

Inv(3) Acute Myeloid Leukemia in a Young Adult and Review of the Literature

Case Rep Oncol Med. 2023 Nov 11:2023:6628492. doi: 10.1155/2023/6628492. eCollection 2023.

Authors

Carlee Blakemore¹, Sudarshawn Damodharan^{1

2}, Diane Puccetti^{1

2}

Affiliations

¹ Department of Pediatrics, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
² Division of Pediatric Hematology, Oncology and Bone Marrow Transplant, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.

Abstract

Acute myeloid leukemia (AML) with the high-risk variant inv(3)/t(3;3) or t(3;3)(q21;26.2) is rarely seen in the pediatric and young adult population. It is associated with poor outcomes with ineffective therapeutic options. Here, we present a case of an 18-year-old female with treatment refractory inv(3) AML in whom remission was unable to be obtained. Better treatment options are needed given the increased resistance to traditional therapy this subtype portrays. Here, we review the literature on pediatric and young adult inv(3) AML along with newer therapeutic options.

Publication types

Case Reports